Free tool
FAERS Monitor: Ryzumvi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217064 or its brand name (Ryzumvi, Phentolamine Mesylate). Reports on generic versions are filed under their own applications.
Reports
139
Serious
91
65% of reports
Hospitalization
44
Death reported
11
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ocular hyperaemia20
- blood urea increased14
- blood glucose increased13
- neutrophil count increased13
- anaemia12
- diarrhoea12
- headache12
- hypertension12
- lymphocyte count decreased12
- drug ineffective11
- dizziness10
- haemoglobin decreased10
- abdominal distension9
- blood pressure increased9
- eye pain9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 2 |
| 2007 | 6 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 15 |
| 2012 | 5 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 15 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 20 |
| 2025 | 26 |
| 2026 | 12 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,020 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neutrophil count increasedSignal | 13 | 192.4 | 114.6 | 2,285 |
| blood urea increasedSignal | 14 | 126.7 | 77.1 | 1,622 |
| lymphocyte count decreasedSignal | 12 | 102.8 | 59.8 | 1,110 |
| ocular hyperaemiaSignal | 20 | 63.8 | 42.5 | 1,176 |
| eye painSignal | 9 | 24.1 | 12.8 | 178 |
| haemoglobin decreasedSignal | 10 | 14.7 | 8.1 | 115 |
| abdominal distensionSignal | 9 | 13.0 | 6.9 | 89 |
| blood glucose increasedSignal | 13 | 10.4 | 6.2 | 103 |
| anaemiaSignal | 12 | 9.5 | 5.5 | 84 |
| blood pressure increasedSignal | 9 | 8.9 | 4.7 | 56 |
| hypertensionSignal | 12 | 8.6 | 5.0 | 74 |
| dizzinessSignal | 10 | 3.0 | 1.7 | 12 |
| headacheSignal | 12 | 2.9 | 1.7 | 13 |
| diarrhoeaSignal | 12 | 2.8 | 1.6 | 13 |
| drug ineffective | 11 | 1.3 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.